tcmc Highlights CAR-T Innovation at BioJapan 2025, Catalyzing Taiwan-Japan Cancer Cell Therapy Partnerships
TOKYO, Oct. 1, 2025 /PRNewswire/ -- Taiwan Cell Manufacturing Company (tcmc), a state-of-the-art CDMO specializing in cell and gene therapy (CGT) manufacturing, is participating in BioJapan 2025 - Asia's premier biotechnology exhibition – taking place October 8-10 in Yokohama, Japan. At this influential event, tcmc will showcase its world-class CDMO services, foster strategic collaborations, and champion innovation in CAR-T cell therapy and regenerative medicine across Asia and beyond.
tcmc is Taiwan's PIC/S GMP-compliant facility dedicated to the commercial manufacturing of genetically modified cells, and one of the few specialized platforms in Asia focusing exclusively on CGT. With the mission of becoming "the central hub of cell therapy manufacturing in Asia," tcmc provides seamless, end-to-end CDMO services, from preclinical development to clinical and commercial-scale production. Its expertise spans CAR-T, NK cells, DC cells and other cell-based therapies, supported by rigorous CMC processes. By delivering customized solutions that meet international standards, tcmc serves as a vital bridge between Asia's biotech innovation and the global marketplace.
tcmc is specializing in next-generation genetically engineered cell therapies, with a particular focus on CAR-T. Its platforms are designed for high purity, efficient cell expansion, and full clinical traceability. tcmc also offers robust capabilities in viral vector development—including Lentivirus—and large-scale production, delivering safe and reliable gene transfer tools for advanced therapies. With closed-system facilities, tcmc ensures minimal contamination risk and maximum manufacturing efficiency. Its excellence in quality management, cost-effectiveness, and scalable production has earned it the reputation of being the 'TSMC of the CGT industry.' This enables tcmc to support biotech startups in accelerating clinical programs and help global pharmaceutical companies bring transformative therapies to market faster.
CAR-T therapies are reshaping the future of cancer treatment. As renowned oncologist José Baselga once said, "Progress in cancer treatment is not a solo sprint, but a global relay race." Building on its integrated CAR-T and CGT manufacturing, tcmc is committed to fostering partnerships and advancing the adoption of cell therapies across Asia and around the world. Following its strong presence at the BIO International Convention 2025 in Boston, tcmc now turns to Japan - leveraging geographic proximity and cultural ties to deepen collaboration and drive the growth of the Asian cell therapy ecosystem. tcmc warmly invites industry professionals, partners, and media to visit Booth No. B-77 at BioJapan 2025 and join tcmc in shaping a healthier future.
SOURCE tcmc
Share this article